Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.58 +0.24 (+0.85%)
Official Closing Price Updated: 7:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,786,953
Open 28.29
Bid (Size) 28.61 (1)
Ask (Size) 28.66 (1)
Prev. Close 28.34
Today's Range 28.24 - 28.59
52wk Range 25.20 - 34.08
Shares Outstanding 5,606,688,356
Dividend Yield 5.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Election Outcome Presents Opportunity For Investors
Let’s break down the key sectors that stand to gain from a Trump or Harris presidency and explore the risks investors should be aware of heading into this election outcome. 
Via Talk Markets
Topics Government
Exposures Political
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily

Performance

YTD
-3.87%
-3.87%
1 Month
+0.99%
+0.99%
3 Month
+1.89%
+1.89%
6 Month
+7.24%
+7.24%
1 Year
-14.20%
-14.20%

More News

Read More
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
Behind the Scenes of Pfizer's Latest Options Trends
Via Benzinga
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Via Benzinga
3 Stocks Set to Benefit from Cooling Inflation Trends
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Is Pfizer a Buy Right Now or a Value Trap?
Via The Motley Fool
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Via Benzinga
3 Sensational Ultrahigh-Yield Dividend Stocks That Make for No-Brainer Buys in the 4th Quarter (and Beyond)
Via The Motley Fool
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
Via The Motley Fool
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
The Covid Era Tech Promises To Reinvent Cancer Treatment
Via Benzinga
Exposures COVID-19
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Via Benzinga
Top 3 Discounted Value Stocks Worth Buying Now
Via Talk Markets
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Via Benzinga
Exposures COVID-19
Is Summit Therapeutics Stock a Buy?
Via The Motley Fool
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.